Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp > re - Not good for the potential of apabetalone as a Covid-19

<< Previous

Bullboard Posts

Next >>

Comment by narmacon Nov 29, 2021 3:25pm

150 Views

Post# 34177077

RE:re - Not good for the potential of apabetalone as a Covid-19

,,yea,,,boooyyy,,,hammer that share price,,,hammer it big time!!!!,,,,,,sell those shares into the market at what ever the bid is on the board,,,,these achievments from our team will certainly garner more DSUs and RSUs next quarter,,,wooohoooo!!! ,,,this company is nothing short of a joke,,,,

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale